Statin use and its implications on survival and disease
progression in the European MultiPartner idiopathic pulmonary
fibrosis registry (EMPIRE)

J 2026

Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)

LANG, David; Bernd LAMPRECHT; Nesrin MOGULKOC; Martina STERCLOVA; Katarzyna B LEWANDOWSKA et al.

Základní údaje

Originální název

Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)

Autoři

Vydání

Annals of Medicine, ABINGDON, TAYLOR & FRANCIS LTD, 2026, 0785-3890

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.300 v roce 2024

Označené pro přenos do RIV

Ano

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Cardiovascular disease; event-free survival; fibrotic lung disease; mortality; IPF; prognosis

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 1. 4. 2026 13:12, Mgr. Tereza Miškechová

Anotace

V originále

Background and objectives: While recent data imply an association of statin use with improved prognosis in idiopathic pulmonary fibrosis (IPF), older reports suggested an increased risk of interstitial lung diseases development. We investigated the association of statin medication with survival and disease progression in the European MultiPartner IPF Registry (EMPIRE). Patients and methods: Patients with at least one year of follow-up and documented statin and/or antifibrotic treatment status from registry inclusion on were selected. Overall- and event-free survival (OS/EFS) were assessed, EFS was defined as either decline in >= 10% predicted relative forced vital capacity (FVC), >= 15% in diffusion capacity for carbon monoxide (DLCO), IPF exacerbation, respiratory hospitalization, and all-cause death. Results were adjusted for sex, age, baseline FVC, antifibrotic treatment status, presence of cardiovascular disease including diabetes, and time since IPF diagnosis. Results: Of 2,669 patients selected, 739 (27.7%) reported statin use and had longer OS than non-users (HR 0.79 (95% CI 0.69-0.9, p < 0.001). Adjusted OS however did not differ by statin use vs. non-use (HR 0.90 (95% CI 0.78-1.04), p = 0.16). In exploratory subgroup analyses according to statin and antifibrotic treatment status, significant differences in unadjusted OS were observed in patients not receiving antifibrotics (statin present vs. absent, HR 0.64 (95% CI 0.5-0.81), p < 0.001)), but not after adjusting for covariates. There were no meaningful differences in EFS according to statin treatment with or without concurrent antifibrotics. Conclusions: We did not observe significant associations of statin treatment with outcomes in IPF patients in the EMPIRE registry.

Citovat

LANG, David; Bernd LAMPRECHT; Nesrin MOGULKOC; Martina STERCLOVA; Katarzyna B LEWANDOWSKA; Mordechai R KRAMER; Vladimir BARTOS; Martina PLACKOVA; Veronika MULLER; Petra OVESNÁ; Michael STUDNICKA a Martina KOZIAR VASAKOVA. Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE). Annals of Medicine. ABINGDON: TAYLOR & FRANCIS LTD, 2026, roč. 58, č. 1, s. 1-10. ISSN 0785-3890. Dostupné z: https://doi.org/10.1080/07853890.2026.2616978.

@article{2564277,
   author = {Lang, David and Lamprecht, Bernd and Mogulkoc, Nesrin and Sterclova, Martina and Lewandowska, Katarzyna B and Kramer, Mordechai R and Bartos, Vladimir and Plackova, Martina and Muller, Veronika and Ovesná, Petra and Studnicka, Michael and Koziar Vasakova, Martina},
   article_location = {ABINGDON},
   article_number = {1},
   doi = {https://doi.org/10.1080/07853890.2026.2616978},
   keywords = {Cardiovascular disease; event-free survival; fibrotic lung disease; mortality; IPF; prognosis},
   language = {eng},
   issn = {0785-3890},
   journal = {Annals of Medicine},
   title = {Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)},
   url = {https://www.tandfonline.com/doi/full/10.1080/07853890.2026.2616978},
   volume = {58},
   year = {2026}
}

TY  - JOUR
ID  - 2564277
AU  - Lang, David - Lamprecht, Bernd - Mogulkoc, Nesrin - Sterclova, Martina - Lewandowska, Katarzyna B - Kramer, Mordechai R - Bartos, Vladimir - Plackova, Martina - Muller, Veronika - Ovesná, Petra - Studnicka, Michael - Koziar Vasakova, Martina
PY  - 2026
TI  - Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE)
JF  - Annals of Medicine
VL  - 58
IS  - 1
SP  - 1-10
EP  - 1-10
PB  - TAYLOR & FRANCIS LTD
SN  - 07853890
KW  - Cardiovascular disease
KW  - event-free survival
KW  - fibrotic lung disease
KW  - mortality
KW  - IPF
KW  - prognosis
UR  - https://www.tandfonline.com/doi/full/10.1080/07853890.2026.2616978
N2  - Background and objectives: While recent data imply an association of statin use with improved prognosis in idiopathic pulmonary fibrosis (IPF), older reports suggested an increased risk of interstitial lung diseases development. We investigated the association of statin medication with survival and disease progression in the European MultiPartner IPF Registry (EMPIRE). Patients and methods: Patients with at least one year of follow-up and documented statin and/or antifibrotic treatment status from registry inclusion on were selected. Overall- and event-free survival (OS/EFS) were assessed, EFS was defined as either decline in >= 10% predicted relative forced vital capacity (FVC), >= 15% in diffusion capacity for carbon monoxide (DLCO), IPF exacerbation, respiratory hospitalization, and all-cause death. Results were adjusted for sex, age, baseline FVC, antifibrotic treatment status, presence of cardiovascular disease including diabetes, and time since IPF diagnosis. Results: Of 2,669 patients selected, 739 (27.7%) reported statin use and had longer OS than non-users (HR 0.79 (95% CI 0.69-0.9, p < 0.001). Adjusted OS however did not differ by statin use vs. non-use (HR 0.90 (95% CI 0.78-1.04), p = 0.16). In exploratory subgroup analyses according to statin and antifibrotic treatment status, significant differences in unadjusted OS were observed in patients not receiving antifibrotics (statin present vs. absent, HR 0.64 (95% CI 0.5-0.81), p < 0.001)), but not after adjusting for covariates. There were no meaningful differences in EFS according to statin treatment with or without concurrent antifibrotics. Conclusions: We did not observe significant associations of statin treatment with outcomes in IPF patients in the EMPIRE registry.
ER  -

LANG, David; Bernd LAMPRECHT; Nesrin MOGULKOC; Martina STERCLOVA; Katarzyna B LEWANDOWSKA; Mordechai R KRAMER; Vladimir BARTOS; Martina PLACKOVA; Veronika MULLER; Petra OVESNÁ; Michael STUDNICKA a Martina KOZIAR VASAKOVA. Statin use and its implications on survival and disease progression in the European MultiPartner idiopathic pulmonary fibrosis registry (EMPIRE). \textit{Annals of Medicine}. ABINGDON: TAYLOR \&{} FRANCIS LTD, 2026, roč.~58, č.~1, s.~1-10. ISSN~0785-3890. Dostupné z: https://doi.org/10.1080/07853890.2026.2616978.

Přehled o publikaci